# Community Review: Reasoning Integrity of a Distilled Genomics Model

We distilled a Qwen3-8B student model to classify germline variants (BRCA1/2 and related genes) under ACMG/AMP guidelines. On held-out ClinVar labels it reaches ~90% accuracy, beating both an InterVar-style rule baseline (75.5%) and its own DeepSeek-R1 teacher (69.4%).

**What we need from you:** clinical-genomics expertise to audit whether the model's *reasoning* is sound - not just whether the label is right. This is the last unchecked acceptance criterion (target: ≥ 70% of 50 cases pass).

**How to review:** each case below shows the variant evidence given to the model, its predicted label/confidence, and its full reasoning trace. Apply the rubric and record `PASS`, `FAIL`, or `BORDERLINE` per case (optionally with a one-line note). The ClinVar label is deliberately hidden to keep the review blind. Submit verdicts however is easiest - a filled copy of this file, a spreadsheet, or a list like `1: PASS, 2: FAIL (invented CADD score), ...`.

## Review rubric - what counts as "integrity"

Judge the **reasoning**, not the final label. A case **FAILS** if any of these hold:

1. **Invalid criterion** - an ACMG/AMP code is triggered that does not apply
   (e.g., claiming BA1 with a gnomAD AF far below 5%).
2. **Fabricated evidence** - a number or fact is cited that is not present in
   the variant evidence (e.g., an invented CADD score).
3. **Incomplete check** - the trace does not check BOTH pathogenic and benign
   criteria before concluding.
4. **Incoherent logic** - the conclusion contradicts the stated criteria
   (e.g., argues benign throughout, then outputs Pathogenic).

Otherwise the case **PASSES** - even if you suspect the final label is wrong.
Use **BORDERLINE** sparingly, when a violation is ambiguous.

---

## Case 1

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.6938-12_6938-10del
- HGVS (protein): N/A
- Type: Deletion
- gnomAD AF: 4.806858407414599e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a deletion at the canonical splice acceptor site (c.6938-12_6938-10del) in BRCA2, a gene where loss-of-function is a well-established disease mechanism for hereditary breast and ovarian cancer. This variant is predicted to disrupt splicing and cause a null effect. PM2 is triggered due to the very low population frequency in gnomAD (4.8e-05), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (4.8e-05) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease like BRCA2-associated disorders. BP4 is not triggered because in silico predictions (CADD, SIFT, PolyPhen) are not available. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 2

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.1739T>C (p.Ile580Thr)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 1e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Ile580Thr), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 1e-05 (0.001%), which is very low and supports pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to lack of evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to lack of evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (1e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for a rare autosomal dominant disease like hereditary breast and ovarian cancer associated with BRCA2. BS2-BS4 are not triggered due to lack of evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to lack of evidence (e.g., no in silico predictions, no alternate cause data, etc.). Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 3

**Variant evidence:**

- Gene: MLH1
- HGVS (coding): NM_000249.4(MLH1):c.2129A>C (p.Asn710Thr)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 9.777459376304389e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Asn710Thr), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is very low (9.777459376304389e-05, approximately 0.009777%), which is below typical thresholds for rare diseases like hereditary breast and ovarian cancer associated with MLH1, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.009777%) is less than 5% (0.05). BS1 is not triggered because the frequency is low and not greater than expected for a rare disease like hereditary breast and ovarian cancer. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because MLH1 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability (e.g., no in silico predictions, no synonymous change, etc.). Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 4

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.-39-17_-39-16insAG
- HGVS (protein): N/A
- Type: Insertion
- gnomAD AF: 0.003378202093426461
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not triggered because the variant is an intronic insertion (c.-39-17_-39-16insAG) and not a canonical null variant (e.g., nonsense, frameshift) in the coding region; no evidence indicates it affects splicing. PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change, de novo, or functional studies). PM1 is not triggered as the variant is intronic and not in a known mutational hot spot or functional domain. PM2 is not triggered because the gnomAD allele frequency is 0.003378 (approximately 0.34%), which is not absent or very low enough for a rare autosomal dominant disorder like BRCA2-associated cancer. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico predictions, or other supporting data). No pathogenic criteria are met.

Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.003378) is less than 5% (0.05). BS1 is triggered because the allele frequency of 0.34% is greater than expected for a pathogenic variant in BRCA2, a gene where disease-causing variants are typically very rare (often <0.1% in population databases). This provides strong evidence for benign impact. BS2-BS4 are not triggered due to lack of evidence (e.g., no healthy adult observation or functional studies). BP1-BP7 are not triggered; specifically, BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not available.

Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic evidence. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign.

Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 5

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.8954-37T>G
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.003358049230030775
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not triggered because the variant is an intronic variant (c.8954-37T>G) and not a canonical splice site or null variant in the coding region; no evidence indicates it affects splicing. PS1-PS4 are not triggered due to lack of evidence for same amino acid change, de novo occurrence, functional studies, or prevalence in affected individuals. PM1 is not triggered as the variant is intronic and not in a known mutational hot spot or functional domain. PM2 is not triggered because the gnomAD allele frequency is 0.003358 (approximately 0.3358%), which is not absent or very low enough for a dominant disorder like BRCA2-associated cancer. PM3-PM6 are not triggered due to no evidence for recessive trans configuration, protein length changes, other missense changes, or de novo occurrence. PP1-PP5 are not triggered due to no evidence for cosegregation, in silico predictions, phenotype specificity, or reputable sources. No pathogenic criteria are met.

Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.003358) is less than 5% (0.05). BS1 is triggered because the allele frequency of 0.003358 (0.3358%) is greater than the expected frequency for a pathogenic variant in BRCA2, which is associated with rare autosomal dominant disorders with high penetrance; pathogenic variants in such genes typically have frequencies well below 0.1% (e.g., <0.001), making this frequency too high for pathogenicity. BS2-BS4 are not triggered due to no evidence for healthy adult observation, functional studies, or lack of segregation. BP1-BP7 are not triggered; specifically, BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not available.

Step 3: Combine criteria. Only BS1 (strong benign criterion) is triggered, with no pathogenic evidence. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign.

Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 6

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.5865A>C (p.Ser1955=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.014758215052438834
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Ser1955=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (1.4758%) is not low or absent from controls. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico predictions, or other supporting data). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.014758, approximately 1.48%) is less than 5% (0.05). BS1 is triggered because the allele frequency (1.48%) is greater than expected for a pathogenic variant in BRCA2, which is associated with rare autosomal dominant hereditary breast and ovarian cancer syndromes; pathogenic variants in such genes typically have frequencies well below 0.1% (e.g., <0.001), making 1.48% too high for pathogenicity. BS2-BS4 and BP1-BP7 are not triggered due to lack of evidence (e.g., no functional studies, no data on missense variants, in silico predictions, or other benign indicators). Step 3: Combine criteria. Only BS1 (strong benign criterion) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 7

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.2469T>A (p.Ala823=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.001
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Ala823=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (0.001) is not sufficiently low for a dominant disorder like BRCA2-associated cancer. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico data, or other supporting information). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.001) is less than 5% (0.05). BS1 is triggered because the allele frequency (0.001, 0.1%) is greater than expected for a pathogenic variant in BRCA2, a gene where pathogenic variants are typically very rare (often <0.01% in population databases). This provides strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not triggered due to lack of evidence (e.g., no functional studies, no data on missense variants, in silico predictions, or other benign indicators). Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 8

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.6249T>C (p.Phe2083=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.001
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Phe2083=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (0.001) is not sufficiently low for a dominant disorder like BRCA2-associated cancer. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico data, or other supporting information). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.001) is less than 5% (0.05). BS1 is triggered because the allele frequency (0.001, 0.1%) is greater than expected for a pathogenic variant in BRCA2, a gene where pathogenic variants are typically very rare (often <0.01% in population databases). BP4 is not triggered due to lack of in silico prediction data (CADD, SIFT, PolyPhen not provided). BP7 is not triggered as no splicing prediction information is available to assess impact. Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 9

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.10237A>G (p.Thr3413Ala)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.015433698994159306
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Thr3413Ala), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (1.54%) is not low or absent from controls. PM3-PM6 and PP1-PP5 are not applicable or not provided. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0154, 1.54%) is less than 5% (0.05). BS1 is triggered because the allele frequency (1.54%) is greater than the expected frequency for a pathogenic variant in BRCA2-associated hereditary breast and ovarian cancer (typically <0.1% for rare diseases), providing strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not applicable or not provided. Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic evidence. According to ACMG guidelines, one strong benign criterion (BS1) supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 10

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.5504dup (p.Asn1835fs)
- HGVS (protein): N/A
- Type: Duplication
- gnomAD AF: 1.6616936403365964e-06
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a frameshift duplication (c.5504dup, p.Asn1835fs) in BRCA2, a gene where loss-of-function is a well-established mechanism for hereditary breast and ovarian cancer, making it a null variant. PM2 is triggered due to the very low population frequency in gnomAD (1.66e-06), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (1.66e-06) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease like hereditary breast and ovarian cancer. BP4 is not triggered because in silico predictions (CADD, SIFT, PolyPhen) are not available. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other pathogenic criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 11

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.8011_8016dup (p.Ile2672_Lys2673insAlaIle)
- HGVS (protein): N/A
- Type: Duplication
- gnomAD AF: 0.0028255531985048868
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not triggered because the variant is an in-frame duplication (p.Ile2672_Lys2673insAlaIle) in BRCA2, not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 0.0028255531985048868 (approximately 0.28%), which is very low and below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to lack of evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.28%) is less than 5% (0.05). BS1 is not triggered because the frequency (0.28%) is less than the typical threshold of 1% (0.01) for rare diseases. BS2-BS4 are not triggered due to no evidence. BP1 is not applicable as the variant is not missense. BP2-BP7 are not triggered due to no evidence or inapplicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 12

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.1422T>G (p.Leu474=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0012171203951241382
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Leu474=), not a null variant. PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (0.0012 in gnomAD) is not extremely low enough for a dominant disorder like BRCA2-associated cancer. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico data, or other supporting evidence). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0012) is less than 5% (0.05). BS1 is triggered because the allele frequency of 0.0012 (approximately 0.12%) is greater than expected for a pathogenic variant in BRCA2, a gene where pathogenic variants are typically very rare (often <0.01% in population databases). This provides strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not triggered due to lack of evidence (e.g., no functional studies, no data on missense variants, in silico predictions, or other benign indicators). Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 13

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.4611del (p.Glu1537fs)
- HGVS (protein): N/A
- Type: Deletion
- gnomAD AF: 1.0123476280309159e-06
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a frameshift deletion (c.4611del, p.Glu1537fs) in BRCA2, a gene where loss-of-function is a well-established mechanism for hereditary breast and ovarian cancer, making it a null variant. PM2 is triggered due to the very low population frequency in gnomAD (1.0123476280309159e-06), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency is not >5% (it is 1.01e-06). BS1 is not triggered because the frequency is not greater than expected for the disease (it is extremely low and consistent with pathogenicity). BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not provided. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other pathogenic criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 14

**Variant evidence:**

- Gene: MLH1
- HGVS (coding): NM_000249.4(MLH1):c.884+13C>T
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0046243616065817506
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is an intronic variant (c.884+13C>T) and not a null variant (e.g., nonsense, frameshift) in the coding region. PS1-PS4 are not triggered due to lack of evidence: no same amino acid change as known pathogenic variant (PS1), no de novo data (PS2), no functional studies (PS3), and no prevalence in affected individuals (PS4). PM1-PM6 are not triggered: PM1 is for missense variants in critical domains, not applicable; PM2 is not triggered as the variant is present in gnomAD with an allele frequency of 0.46% (not absent from controls); PM3-PM6 lack evidence. PP1-PP5 are not triggered due to no cosegregation, in silico data, or other supporting evidence. No pathogenic criteria are met.

Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.004624, approximately 0.46%) is less than 5% (0.05). BS1 is triggered because the allele frequency of 0.46% is greater than the expected frequency for a pathogenic variant in MLH1, which is associated with autosomal dominant hereditary cancer syndromes like Lynch syndrome. Pathogenic variants in such genes typically have very low population frequencies (often <0.1%), and a frequency of 0.46% is too high for a pathogenic variant, providing strong evidence for benign impact. BS2-BS4 are not triggered due to no evidence of observation in healthy adults, functional studies, or lack of segregation. BP1-BP7 are not triggered: BP1 is for missense variants, not intronic; BP4 requires in silico data suggesting no impact, but CADD, SIFT, and PolyPhen scores are not provided; other BP criteria lack evidence.

Step 3: Combine criteria. Only BS1 (strong benign criterion) is triggered, with no pathogenic criteria. According to ACMG/AMP guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign.

Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 15

**Variant evidence:**

- Gene: MLH1
- HGVS (coding): NM_000249.4(MLH1):c.2146G>C (p.Val716Leu)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.01
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Val716Leu), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (1%) is not sufficiently low for a rare disease like hereditary breast and ovarian cancer associated with MLH1. PM3-PM6 and PP1-PP5 are not applicable or not provided. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.01) is less than 5% (0.05). BS1 is triggered because the allele frequency of 1% (0.01) is greater than expected for a pathogenic variant in MLH1, where pathogenic variants are typically very rare (often <0.1% in population databases). This provides strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not applicable or not provided. Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 16

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.7841T>A (p.Leu2614His)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.02793851841495418
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Leu2614His), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (2.79%) is not low or absent from controls. PM3-PM6 and PP1-PP5 are not applicable or not provided. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0279, 2.79%) is less than 5% (0.05). BS1 is triggered because the allele frequency (2.79%) is greater than the expected frequency for pathogenic variants in BRCA2-associated hereditary breast and ovarian cancer (typically <0.1% for rare diseases), providing strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not applicable or not provided. Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic evidence. According to ACMG guidelines, one strong benign criterion (BS1) supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 17

**Variant evidence:**

- Gene: MLH1
- HGVS (coding): NM_000249.4(MLH1):c.2056A>T (p.Ile686Phe)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.00039516110290915217
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Ile686Phe), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 0.000395 (approximately 0.0395%), which is very low and below typical thresholds for rare diseases like hereditary breast and ovarian cancer associated with MLH1, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.000395) is less than 5% (0.05). BS1 is not triggered because the frequency is less than 1% (0.01), which is the typical threshold for rare diseases. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because MLH1 is a tumor suppressor where missense variants can be pathogenic, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability (e.g., no in silico predictions, no alternate cause data). Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 18

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.9652T>G (p.Ser3218Ala)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0030352974071280667
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Ser3218Ala), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 0.003035 (approximately 0.3%), which is very low and below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.003035) is less than 5% (0.05). BS1 is not triggered because the frequency is 0.3%, which is less than the typical threshold of 1% (0.01) for rare diseases. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 is a tumor suppressor where missense variants can be pathogenic, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability (e.g., no in silico predictions, no alternate cause data). Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 19

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.10167T>A (p.Ser3389=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0014727203226458053
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Ser3389=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (0.00147, approximately 0.147%) is not sufficiently low for a rare autosomal dominant disorder like BRCA2-associated hereditary breast and ovarian cancer, where pathogenic variants are typically very rare (e.g., <0.001%). PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico predictions, or other supporting data). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.00147) is less than 5% (0.05). BS1 is triggered because the allele frequency (0.00147, approximately 0.147%) is greater than expected for a pathogenic variant in BRCA2, where pathogenic variants are typically very rare (e.g., <0.001%). This provides strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not triggered due to lack of evidence (e.g., no functional studies, segregation data, or computational evidence). Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 20

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.7091A>T (p.Glu2364Val)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 9.335414298950555e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Glu2364Val), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is very low (9.335414298950555e-05, approximately 0.0093%), which is below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0093%) is less than 5% (0.05). BS1 is not triggered because the frequency is less than 1% (0.01), which is the typical threshold for rare diseases. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 21

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.4414A>T (p.Lys1472Ter)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 1e-06
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a nonsense mutation (p.Lys1472Ter) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (1e-06), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (1e-06) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease like BRCA2-associated disorders. BP4 is not triggered due to lack of in silico prediction data (CADD, SIFT, PolyPhen not provided). No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 22

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.4948dup (p.Ser1650fs)
- HGVS (protein): N/A
- Type: Duplication
- gnomAD AF: 4.0182798832334195e-06
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a frameshift duplication (p.Ser1650fs) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (4.02e-06), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (4.02e-06) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease like BRCA2-associated disorders. BP4 is not triggered due to lack of in silico prediction data (CADD, SIFT, PolyPhen not provided). No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 23

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.8567A>G (p.Glu2856Gly)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.5
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Glu2856Gly), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence: no same amino acid change as known pathogenic variant (PS1), no de novo data (PS2), no functional studies (PS3), and no prevalence in affected individuals (PS4). PM1-PM6 are not triggered: no domain or hot spot information (PM1), allele frequency is 0.5 (not absent or very low) (PM2), no data for recessive trans (PM3), no protein length change (PM4), no different missense at same residue (PM5), and no assumed de novo (PM6). PP1-PP5 are not triggered due to lack of evidence: no cosegregation (PP1), no gene-specific missense rate data (PP2), no in silico predictions (PP3), no phenotype specificity (PP4), and no reputable source (PP5). No pathogenic criteria are met.

Step 2: Check benign criteria. BA1 is triggered because the gnomAD allele frequency is 0.5 (50%), which is greater than the 5% threshold (0.05), providing standalone evidence for benign classification. BS1 is triggered because the allele frequency of 50% is far higher than expected for a pathogenic variant in BRCA2, which is associated with rare autosomal dominant hereditary breast and ovarian cancer syndromes; pathogenic variants typically have very low frequencies (<0.1%). Other benign criteria (BP1-BP7) are not triggered due to lack of evidence: BP4 not applicable as in silico data is N/A, and no other supporting evidence.

Step 3: Combine criteria. BA1 is a standalone benign criterion according to ACMG guidelines, so the variant can be classified as Benign based on this alone. BS1 provides additional strong support.

Conclusion: The variant is classified as Benign with high confidence due to high population frequency and no conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 24

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.6014_6017dup (p.Ser2006delinsArgTer)
- HGVS (protein): N/A
- Type: Duplication
- gnomAD AF: 1.638229267417922e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a null variant (p.Ser2006delinsArgTer) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (1.638229267417922e-05), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.00164%) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease like BRCA2-associated disorders. BP4 is not triggered due to lack of in silico prediction data (CADD, SIFT, PolyPhen not provided). No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 25

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.9649-37A>C
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0012696946480565772
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not triggered because the variant is an intronic variant (c.9649-37A>C) and not a canonical splice site or null variant in the coding region; no evidence indicates it affects splicing. PS1-PS4 are not triggered due to lack of evidence for same amino acid change, de novo occurrence, functional studies, or prevalence in affected individuals. PM1 is not triggered as the variant is intronic and not in a known mutational hot spot or functional domain. PM2 is triggered because the population frequency in gnomAD is 0.00127 (approximately 0.127%), which is very low and below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence for in trans with pathogenic variant, protein length changes, different missense at same residue, or assumed de novo. PP1-PP5 are not triggered due to no evidence for cosegregation, computational predictions (CADD, SIFT, PolyPhen are N/A), phenotype specificity, or reputable source reports. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.00127) is less than 5% (0.05). BS1 is not triggered because the frequency is less than 1% (0.01), which is the typical threshold for rare diseases. BS2-BS4 are not triggered due to no evidence for healthy adult observation, functional studies showing no effect, or lack of segregation. BP1-BP7 are not triggered; specifically, BP4 is not triggered as computational evidence is not available. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 26

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.2227C>T (p.His743Tyr)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 4.6530473316536725e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.His743Tyr), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is very low (4.65e-05), which is below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (4.65e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for the disease (for BRCA2, pathogenic variants are very rare, and this frequency is consistent with rarity). BS2-BS4 are not triggered due to no evidence. BP1 is not triggered because BRCA2 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 27

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.8729A>G (p.Asn2910Ser)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.07545650708993251
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Asn2910Ser), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (7.5457%) is not low or absent from controls. PM3-PM6 and PP1-PP5 are not applicable or not provided. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.075457, approximately 7.55%) is less than 5% (0.05). BS1 is triggered because the allele frequency (7.55%) is greater than expected for a pathogenic variant in BRCA2, which is associated with rare autosomal dominant hereditary breast and ovarian cancer syndromes; pathogenic variants in such genes typically have frequencies well below 1% (e.g., <0.001). Other benign criteria (BS2-BS4, BP1-BP7) are not triggered due to lack of evidence or applicability. Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 28

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.6314T>C (p.Ile2105Thr)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0007235396552867318
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Ile2105Thr), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 0.0007235 (approximately 0.07235%), which is very low and below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0007235) is less than 5% (0.05). BS1 is not triggered because the frequency is less than 1% (0.01), which is the typical threshold for rare diseases. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 is a tumor suppressor where missense variants can be pathogenic, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 29

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.2841G>A (p.Leu947=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.024947414909817493
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Leu947=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence: PS1 (same amino acid change as known pathogenic) not provided, PS2 (de novo) not provided, PS3 (functional studies) not provided, PS4 (prevalence in affected) not provided. PM1-PM6 are not triggered: PM1 (hot spot/critical domain) not specified for synonymous variant, PM2 (absent from controls) not applicable as gnomAD frequency is 2.49%, PM3-PM6 not provided. PP1-PP5 are not triggered due to lack of evidence: PP1 (cosegregation) not provided, PP2 (missense in gene with low benign rate) not applicable as variant is synonymous, PP3 (in silico evidence) not provided, PP4-PP5 not provided. No pathogenic criteria are met.

Step 2: Check benign criteria. BA1 is not triggered because the gnomAD allele frequency (0.0249, 2.49%) is less than 5% (0.05). BS1 is triggered because the allele frequency of 2.49% is greater than expected for a pathogenic variant in BRCA2, which is associated with rare autosomal dominant hereditary breast and ovarian cancer syndromes; pathogenic variants in such genes typically have frequencies well below 1% (e.g., <0.001). Other benign criteria (BS2-BS4, BP1-BP7) are not triggered due to lack of evidence or applicability: BS2-BS4 not provided, BP1-BP7 not applicable or no evidence (e.g., BP4 requires in silico data, which is N/A).

Step 3: Combine criteria. Only BS1 (strong evidence for benign) is triggered, with no pathogenic evidence. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign.

Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 30

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.10129G>C (p.Glu3377Gln)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 9.152234395129069e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Glu3377Gln), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is very low (9.15e-05), which is below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (9.15e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for the disease (for BRCA2, pathogenic variants are very rare, and this frequency is consistent with rarity). BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 31

**Variant evidence:**

- Gene: MLH1
- HGVS (coding): NM_000249.4(MLH1):c.2142G>C (p.Trp714Cys)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 3.79637468060048e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Trp714Cys), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is very low (3.79637468060048e-05), which is below typical thresholds for rare diseases like hereditary breast and ovarian cancer associated with MLH1, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0038%) is far below the 5% threshold. BS1 is not triggered as the frequency is very low and not greater than expected for a rare disease. BS2-BS4 are not triggered due to no evidence. BP1 is not applicable because MLH1 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to no evidence or inapplicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 32

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.1236_1237del (p.Leu413fs)
- HGVS (protein): N/A
- Type: Deletion
- gnomAD AF: 2.497875374384988e-06
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a frameshift deletion (p.Leu413fs) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (2.497875374384988e-06), indicating rarity consistent with pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence.
Step 2: Check benign criteria. BA1 is not triggered because the allele frequency is not >5% (it is 2.5e-06). BS1 is not triggered because the frequency is not greater than expected for the disease (for BRCA2, pathogenic variants are very rare, and this frequency is low). BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not available. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable.
Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other pathogenic criterion (e.g., PM2) supports a Pathogenic classification.
Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 33

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.1270_1286del (p.Ser424fs)
- HGVS (protein): N/A
- Type: Deletion
- gnomAD AF: 1.0617190665114117e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a frameshift deletion (p.Ser424fs) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (1.06e-05), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (1.06e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for the disease (for BRCA2, pathogenic variants are very rare, and this frequency is consistent with rarity). BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not available. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other pathogenic criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 34

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.6725A>T (p.Asp2242Val)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.00021709391552085286
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Asp2242Val), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no information is provided about mutational hot spots or critical domains. PM2 is triggered because the population frequency in gnomAD is 0.000217 (approximately 0.0217%), which is very low and below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length changes, etc.). PP1-PP5 are not triggered due to lack of evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.000217) is less than 5% (0.05). BS1 is not triggered because the frequency is less than 1% (0.01), which is the typical threshold for rare diseases. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 is a tumor suppressor where missense variants can be pathogenic, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 35

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.4400A>T (p.His1467Leu)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0019860951371337182
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.His1467Leu), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 0.001986 (approximately 0.2%), which is very low and below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.001986) is less than 5% (0.05). BS1 is not triggered because the frequency is less than 1% (0.01), which is the typical threshold for rare diseases. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 is a tumor suppressor where missense variants can be pathogenic, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 36

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.1257T>A (p.Cys419Ter)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 5.466687672141919e-06
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a nonsense mutation (p.Cys419Ter) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (5.47e-06), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (5.47e-06) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease like BRCA2-associated disorders. BP4 is not triggered due to lack of in silico prediction data (CADD, SIFT, PolyPhen not provided). No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 37

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.6822dup (p.Glu2275fs)
- HGVS (protein): N/A
- Type: Duplication
- gnomAD AF: 1.6516377508744282e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a frameshift duplication (p.Glu2275fs) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (1.65e-05), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (1.65e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for a rare disease like hereditary breast and ovarian cancer. BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not available. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other pathogenic criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 38

**Variant evidence:**

- Gene: MLH1
- HGVS (coding): NM_000249.4(MLH1):c.2144C>A (p.Thr715Asn)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 3.494491666307262e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Thr715Asn), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is very low (3.49e-05), which is below typical thresholds for rare diseases like hereditary breast and ovarian cancer associated with MLH1, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (3.49e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for the disease (it is very low and consistent with pathogenicity). BS2-BS4 are not triggered due to no evidence. BP1 is not triggered because MLH1 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to no evidence or inapplicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 39

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.1213G>A (p.Gly405Arg)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.0003583012788338823
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Gly405Arg), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 0.000358 (approximately 0.0358%), which is very low and below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.000358) is less than 5% (0.05). BS1 is not triggered because the frequency is less than 1% (0.01), which is the typical threshold for rare diseases. BS2-BS4 are not triggered due to no evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 is a tumor suppressor where missense variants can be pathogenic, not only truncating variants. BP2-BP7 are not triggered due to no evidence or applicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 40

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.5810C>A (p.Ser1937Tyr)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 1e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Ser1937Tyr), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is 1e-05 (0.001%), which is very low and supports pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to lack of evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to lack of evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (1e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for a rare autosomal dominant disease like hereditary breast and ovarian cancer associated with BRCA2. BS2-BS4 are not triggered due to lack of evidence (e.g., no healthy adult data, no functional studies, etc.). BP1 is not triggered because BRCA2 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to lack of evidence (e.g., no in silico predictions, no alternate cause data, etc.). Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 41

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.3:c.7181_7182insALU
- HGVS (protein): N/A
- Type: Insertion
- gnomAD AF: 2.1405583460928622e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a null variant (insertion of ALU element) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to very low population frequency in gnomAD (2.14e-05), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (2.14e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for the disease (for BRCA2, pathogenic variants are very rare, and this frequency is consistent with rarity). BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not available. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other pathogenic criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 42

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.6994T>C (p.Cys2332Arg)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 7.09245121994759e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Variant of Uncertain Significance (confidence: Low)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is a missense (p.Cys2332Arg), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not triggered as no domain or hot spot information is provided. PM2 is triggered because the population frequency in gnomAD is very low (7.09245121994759e-05), which is below typical thresholds for rare diseases like BRCA2-associated disorders, supporting pathogenicity as a moderate criterion. PM3-PM6 are not triggered due to no evidence (e.g., no de novo data, no protein length change, etc.). PP1-PP5 are not triggered due to no evidence (e.g., no cosegregation, no in silico predictions, etc.). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.00709%) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease (typically >1% might trigger). BS2-BS4 are not triggered due to no evidence. BP1 is not applicable because BRCA2 can have pathogenic missense variants, not only truncating variants. BP2-BP7 are not triggered due to no evidence or inapplicability. Step 3: Combine criteria. Only PM2 (moderate pathogenic) is triggered, with no other pathogenic or benign criteria. According to ACMG guidelines, a single moderate criterion is insufficient for Likely Pathogenic or Pathogenic classification, and no benign criteria are met. Therefore, the variant is classified as Variant of Uncertain Significance (VUS).

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 43

**Variant evidence:**

- Gene: MLH1
- HGVS (coding): NM_000249.4(MLH1):c.116+15G>A
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.1
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not triggered because the variant is an intronic variant (c.116+15G>A) and not a null variant (e.g., nonsense, frameshift) in the coding region. PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change, de novo, or functional studies). PM1-PM6 are not triggered; specifically, PM2 is not triggered because the population frequency is 0.1 (10%), indicating presence in controls. PP1-PP5 are not triggered due to lack of evidence (e.g., no cosegregation, in silico data, or phenotype specificity). No pathogenic criteria are met.

Step 2: Check benign criteria. BA1 is triggered because the gnomAD allele frequency is 0.1 (10%), which is greater than the 5% threshold (0.05), providing standalone evidence for benign classification. BS1 is triggered because the frequency of 10% is far higher than expected for a pathogenic variant in MLH1, an autosomal dominant gene where disease-causing variants are typically very rare (e.g., <0.1%). Other benign criteria (BP1-BP7) are not triggered due to lack of evidence or applicability (e.g., BP4 not applicable as in silico data is N/A).

Step 3: Combine criteria. BA1 is a standalone benign criterion according to ACMG guidelines, so no additional criteria are required. The high frequency further supports BS1, but BA1 alone is sufficient.

Conclusion: The variant is classified as Benign with high confidence due to clear population frequency evidence and no conflicting pathogenic evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 44

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.5577T>A (p.Ile1859=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.06516242947038693
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Ile1859=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (6.52%) is not low or absent from controls. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico predictions, or other supporting data). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0652, 6.52%) is less than 5% (0.05). BS1 is triggered because the allele frequency (6.52%) is greater than expected for a pathogenic variant in BRCA2, which is associated with rare autosomal dominant hereditary breast and ovarian cancer syndromes; pathogenic variants in such genes typically have frequencies well below 1% (e.g., <0.001). BP4 is not triggered due to lack of in silico prediction data (CADD, SIFT, PolyPhen not provided). BP7 is not triggered because no splicing prediction algorithms or conservation data are available to assess impact. Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 45

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.10036T>C (p.Leu3346=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.043894619718290846
- gnomAD filter: COMMON
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Leu3346=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence: no same amino acid change as known pathogenic variant (PS1), no de novo data (PS2), no functional studies (PS3), and no prevalence in affected individuals (PS4). PM1-PM6 are not triggered: no domain or hot spot information (PM1), allele frequency is 4.39% in gnomAD, which is not low enough for PM2 (typically PM2 requires absence or very low frequency, e.g., <0.001) and is actually high, so PM2 is not met; no data for other PM criteria. PP1-PP5 are not triggered due to lack of evidence: no cosegregation, in silico predictions, or other supporting data. No pathogenic criteria are met.

Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0439, 4.39%) is less than 5% (0.05). BS1 is triggered because the allele frequency of 4.39% is greater than expected for a pathogenic variant in BRCA2, which is associated with rare autosomal dominant hereditary breast and ovarian cancer syndromes. Pathogenic variants in such genes typically have frequencies well below 1% (e.g., <0.001), and a frequency of 4.39% is too high for a pathogenic variant, providing strong evidence for benign impact. BS2-BS4 are not triggered due to lack of evidence: no healthy adult data (BS2), no functional studies (BS3), and no segregation data (BS4). BP1-BP7 are not triggered: BP1 is for missense variants in genes where only LOF is pathogenic, but this is a synonymous variant; BP4 requires in silico predictions suggesting no impact, but CADD, SIFT, and PolyPhen are not provided; other BP criteria lack evidence.

Step 3: Combine criteria. Only BS1 (strong benign criterion) is triggered, with no pathogenic criteria. According to ACMG/AMP guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign.

Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 46

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.9934del (p.Pro3311_Ile3312insTer)
- HGVS (protein): N/A
- Type: Deletion
- gnomAD AF: 1e-05
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a deletion leading to a frameshift and premature termination (p.Pro3311_Ile3312insTer), which is a null variant. BRCA2 is a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (1e-05), indicating rarity consistent with pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence.
Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (1e-05) is less than 5% (0.05). BS1 is not triggered because the frequency is not greater than expected for the disease (for BRCA2, pathogenic variants are very rare, and 1e-05 is consistent with this). BP4 is not triggered as in silico predictions (CADD, SIFT, PolyPhen) are not available. No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable.
Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG/AMP guidelines, PVS1 with at least one other pathogenic criterion (e.g., PM2) supports a Pathogenic classification.
Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 47

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.7668T>C (p.Asn2556=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.004438767060339792
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Asn2556=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (0.0044 in gnomAD) is not very low enough for a rare autosomal dominant disorder like BRCA2-associated cancer. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico predictions, or other supporting data). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.0044) is less than 5% (0.05). BS1 is triggered because the allele frequency (0.0044, approximately 0.44%) is greater than expected for a pathogenic variant in BRCA2, a gene where pathogenic variants are typically very rare (often <0.1% in population databases). This provides strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not triggered due to lack of evidence (e.g., no functional studies, no data on healthy individuals, no computational evidence, etc.). Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 48

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.5097del (p.Asp1699fs)
- HGVS (protein): N/A
- Type: Deletion
- gnomAD AF: 0.0
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a frameshift deletion (c.5097del, p.Asp1699fs) in BRCA2, a gene where loss-of-function is a well-established mechanism for hereditary breast and ovarian cancer, making it a null variant. PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change, de novo, or functional studies). PM1-PM6 are not triggered; specifically, PM2 is not triggered as population frequency is not provided. PP1-PP5 are not triggered due to lack of evidence (e.g., no cosegregation or in silico data). Step 2: Check benign criteria. BA1 is not triggered because allele frequency in gnomAD is not available. BS1 is not triggered due to lack of frequency data. BS2-BS4 and BP1-BP7 are not triggered due to no evidence (e.g., BP4 not applicable as in silico predictions are not provided). Step 3: Combine criteria. Only PVS1 (Very Strong pathogenic) is triggered, with no benign criteria. According to ACMG guidelines, PVS1 alone can be sufficient for Pathogenic classification in genes like BRCA2 where LOF is pathogenic. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and no conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 49

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.4160T>G (p.Leu1387Ter)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 3.992395184982098e-06
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Pathogenic (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is triggered because the variant is a nonsense mutation (p.Leu1387Ter) in BRCA2, a gene where loss-of-function is a known mechanism of disease for hereditary breast and ovarian cancer. PM2 is triggered due to the very low population frequency in gnomAD (3.99e-06), which is below typical thresholds for rare diseases, supporting pathogenicity. No other pathogenic criteria (PS1-PS4, PM1, PM3-PM6, PP1-PP5) are applicable based on the provided evidence. Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (3.99e-06) is far below the 5% threshold. BS1 is not triggered as the frequency is not greater than expected for a rare disease like BRCA2-associated disorders. BP4 is not triggered due to lack of in silico prediction data (CADD, SIFT, PolyPhen not provided). No other benign criteria (BS2-BS4, BP1-BP3, BP5-BP7) are applicable. Step 3: Combine criteria. PVS1 is a Very Strong pathogenic criterion, and PM2 is a Moderate pathogenic criterion. According to ACMG guidelines, PVS1 with at least one other criterion (e.g., PM2) supports a Pathogenic classification. Step 4: Final classification is Pathogenic with High confidence due to clear application of PVS1 and PM2 without conflicting evidence.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---

## Case 50

**Variant evidence:**

- Gene: BRCA2
- HGVS (coding): NM_000059.4(BRCA2):c.7425A>G (p.Glu2475=)
- HGVS (protein): N/A
- Type: single nucleotide variant
- gnomAD AF: 0.001
- gnomAD filter: PASS
- CADD: N/A
- SIFT / PolyPhen: N/A / N/A
- Functional studies: N/A

**Model output:** Likely Benign (confidence: High)

**Reasoning trace:**

> Step 1: Check pathogenic criteria. PVS1 is not applicable because the variant is synonymous (p.Glu2475=), not a null variant (e.g., nonsense, frameshift). PS1-PS4 are not triggered due to lack of evidence (e.g., no same amino acid change as known pathogenic, no functional studies, etc.). PM1 is not applicable as no domain or hot spot information is provided. PM2 is not triggered because the population frequency (0.001) is not sufficiently low for a dominant disorder like BRCA2-associated cancer. PM3-PM6 and PP1-PP5 are not triggered due to lack of evidence (e.g., no de novo, cosegregation, in silico data, or other supporting information). Step 2: Check benign criteria. BA1 is not triggered because the allele frequency (0.001) is less than 5% (0.05). BS1 is triggered because the allele frequency (0.001, 0.1%) is greater than expected for a pathogenic variant in BRCA2, a gene where pathogenic variants are typically very rare (often <0.01% in population databases). This provides strong evidence for benign impact. BS2-BS4 and BP1-BP7 are not triggered due to lack of evidence (e.g., no functional studies, no data on missense variants, in silico predictions, or other benign indicators). Step 3: Combine criteria. Only BS1 (strong benign) is triggered, with no pathogenic criteria. According to ACMG guidelines, one strong benign criterion (BS1) in the absence of pathogenic evidence supports a classification of Likely Benign. Step 4: Final classification is Likely Benign with high confidence due to clear population frequency evidence and no conflicting data.

**Verdict:** `PASS / FAIL / BORDERLINE` - note: ______

---
